TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03212898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anticoagulation care
Description: Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
Study: NCT03041688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00911118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated, image-guided, intensity-modulated external beam radiation
Description: A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if \< 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
Study: NCT03044613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg or 1 mg/kg administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg or 1 mg/kg administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: 80mg administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: standard care dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: standard care dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: standard care dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: standard care dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: standard care dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: standard care dose
Study: NCT01971541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: A validated 8-week group program that teaches mindfulness meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: A validated group program of PTSD treatment, which focuses on cognitive processing.
Study: NCT02005367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Recovery-Horticulture
Description: Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Recovery-Art/Music
Description: Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
Study: NCT03866655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OWise
Description: OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
Study: NCT03309878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01096316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Care Management
Description: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
Study: NCT00287222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/KG I.V. every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg orally every day
Study: NCT01762553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The TEA intervention
Description: TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
Study: NCT04508881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve
Description: To compare the prevalence of postoperative hypotony between the 2 arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve
Description: To compare the prevalence of postoperative hypotony between the 2 arms
Study: NCT01160276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine+colchicine
Description: the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
Study: NCT01514019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acebutolol
Description: Acebutolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule(Capsules filled up with lactose)
Study: NCT03500159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125 200 mg
Description: Synthetic SHIP1 activator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appearance and weight matched tablets without the active product ingredient
Study: NCT04083976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib oral tablets.
Study: NCT03777943

Intervention type: PROCEDURE
Intervention: Sampling peritoneal tissue
Description: Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
Study: NCT02768493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg of 0.15% ropivacaine
Description: Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 ml/kg of 0.15% ropivacaine
Description: Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
Study: NCT04787224

Intervention type: OTHER
Intervention: immediate implant with vestibular socket therapy
Description: A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft \[75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.

Intervention type: OTHER
Intervention: immediate implant with vestibular socket therapy
Description: A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft \[75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.
Study: NCT02088450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active treatment with nitrendipine (10-40 mg/day).
Description: If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active treatment with nitrendipine (10-40 mg/day).
Description: If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
Study: NCT03103126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined resistance exercise and walking
Description: Combined resistance exercise and walking
Study: NCT06394986

Intervention type: PROCEDURE
Intervention: Hemodialysis session
Description: Change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session will be explored.
Study: NCT00887549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Induction Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Induction Therapy: 75 mg/m\^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
Study: NCT02253615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Machines exercises
Description: Resistance training in pneumatic machines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic exercises
Description: Resistance training with elastic tubes.
Study: NCT00759161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: AN2728 Ointment, 5%, twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Ointment Vehicle
Description: AN2728 Ointment Vehicle, twice daily for 4 weeks.
Study: NCT00103168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400 mg/day for 2 years
Study: NCT03846050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAC feedback/warning
Description: Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAC feedback/warning
Description: Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No BAC feedback/warning
Description: Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
Study: NCT00325715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 201904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Study: NCT03015766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure therapy
Description: Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham auricular acupressure therapy
Description: The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
Study: NCT02832934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT02383875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opticourses
Description: An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
Study: NCT01794000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03222700

Intervention type: PROCEDURE
Intervention: surgical procedure
Description: In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.

Intervention type: PROCEDURE
Intervention: surgical procedure
Description: In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
Study: NCT02907515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cm-loc attachment
Description: cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ball attachment
Description: ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
Study: NCT00366002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
Study: NCT02222935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Exercise Training
Description: Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Back exercise program
Description: Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
Study: NCT02869399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention in addition to standard recommendations
Description: The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~* avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~* increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~* eat mostly food of plant origin~* eat lean meat, limit intake of red meat and avoid processed meat~* increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~* avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries
Study: NCT02314052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-MYC
Description: Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety
Study: NCT02748863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 2 mL form
Description: Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 1 mL form
Description: Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
Study: NCT02624271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples analysis
Description: Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
Study: NCT01618032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA
Description: High velocity and low amplitude manipulation in traction of subtalar jonit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MWM
Description: Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: Manual contact during a period of time similar of teh other interventions
Study: NCT01324817

Intervention type: DEVICE
Intervention: Kai Spot (v 2.1)
Description: The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.

Intervention type: DEVICE
Intervention: Kai Continuous (v 1.0)
Description: The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
Study: NCT02760966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol 70º

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soap
Study: NCT04215926

Intervention type: OTHER
Intervention: No intervention; cross-sectional study
Description: No intervention; cross-sectional study